1. Dzau VJ, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121: 1244–63.
2. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19.
3. Ceconi C, Francolini G, Olivares A et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1–6.
4. Todd PA, Benfield P. Ramipril: а review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990; 39 (1): 110–35.
5. Comini L, Bachetti T, Cargnoni A et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharm Res 2007; 56: 42–8.
6. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41–6.
7. Agabati-Rosei E, Ambriosoni E, Dal Palu C et al. RACE Study Group. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension: results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens 1995; 13: 1325–34.
8. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821–8.
9. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349: 1493–7.
10. Willenheimer R, Juul-Möller S, Forslund L, Erhardt L. No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months. Curr Control Trials Cardiovasc Med 2001; 2 (2): 99–105.
11. Lonn EM, Yusuf S, Doris CI et al. Effects of ramipril and vitamin E on atherosclerosis. Circulation 2001; 103: 919–25.
12. The GISEN Group. Randomised placebo-controlled trail of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nefropathy. Lancet 1997; 349: 1857–63.
13. Wright JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421–31.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9.
15. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547–53.
16. Coca A. Cerebral involvement in hypertensive cardiovascular disease. Eur Heart J 2003; 5 (Suppl. F): F19–25.
17. Regenhardt RW. Understanding the Cerebroprotective Actions of the Ace2/Ang-(1-7)/Mas Axis during Ischemic and Hemorrhagic Stroke. ETDs 2012.
18. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 1–5.
19. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008; 358: 1547–59.
20. Ellul J, Archer N, Foy CML et al. The effects of commonly prescribed drugs in patients with Alzheimer’s disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 2007; 78: 233–9.
21. Dong Y-F, Kataoka K, Tokutomi Y et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J 2011; 25: 2911–20.
22. Ohrui T, Tomita N, Sato-Nakagawa et al. Effects of brainpenetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324–5.
23. Qureshi N, Babbar R. Effect of ramipril therapy on cognitive functions in cases of mild to moderate essential hypertension. Indian J Physiol Pharmacol 2007; 51 (1): 40–8.
24. Anderson C, Teo K, Gao P et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology 2011; 10 (1): 43–53.
25. The DREAM Trial Investigators. Effect of Ramipril on the Incidence of Diabetes. N Engl J Med 2006; 355: 1551–62.
26. Zidek W, Schrader J, Lüders S et al. Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. Cardiovasc Diabetology 2012; 11: 1–11.
27. Марцевич С.Ю., Лукина Ю.В., Дмитриева Н.А. и др. Сравнительное исследование нового дженерического препарата рамиприла с оригинальным препаратом у больных артериальной гипертонией и высоким риском развития сердечно-сосудистых осложнений. В кн.: Основы доказательной медицины. 2010.
28. Колос И.П., Мартынюк T.B., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензинпревращающего фермента рамиприлом и его комбинации с гидрохлоротиазидом у пациентов с артериальной гипертонией и избыточной массой тела: исследование ХАРИЗМА. Кардиоваск. терапия и профилактика. 2008; 2 (4): 65–71.
29. Чазова И.Е., Мартынюк T.B., Небиеридзе Д.В. и др. Сравнительная эффективность лечения фиксированными комбинациями различных доз рамиприла и гидрохлоротиазида. Кардиоваск. терапия и профилактика. 2010; 9 (4): 25–31.

М.В.Леонова

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России, Москва